Associate Director Scientific CommunicationsSobi, Stockholm, SwedenStockholm, Stockholms Lan, Sweden
OC 14.1 - Perioperative management with efanesoctocog alfa in adults, adolescents, and children with severe hemophilia A in the phase 3 XTEND clinical program
Sunday, June 23, 202409:30 – 09:45 ICT
OC 50.1 - First interim analysis of clinical outcomes in adults and adolescents with severe hemophilia A receiving efanesoctocog alfa prophylaxis in XTEND-ed, a phase 3 long-term extension study
Tuesday, June 25, 202409:30 – 09:45 ICT
OC 50.2 - Long-term outcomes with efanesoctocog alfa prophylaxis for previously treated children with severe hemophilia A, an interim analysis of the phase 3 XTEND-ed study
Tuesday, June 25, 202409:45 – 10:00 ICT
